Q2 2025 · 13F-HR
Palo Alto Investors LPholdings as filed
Filed 2025-08-14 · accession 0001306923-25-000016
$470.0M
Reported value
45
Positions
2025-06-30
Period end
The Brief · Palo Alto Investors LP · Q2 2025
AI · grounded in 13F
Palo Alto Investors LP established a new position in INSM valued at $87.1M. The fund also initiated new stakes in ACAD for $55.3M and BMRN for $46.2M. Other new additions include AM6, UTHR, and BIIB.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 457669307 | INSM | INSMED INC | $87.1M | 18.5% | 865,113 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $55.3M | 11.8% | 2,563,209 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $46.2M | 9.83% | 840,470 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $32.1M | 6.84% | 5,610,513 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $27.4M | 5.84% | 95,482 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $25.8M | 5.50% | 205,759 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $24.6M | 5.24% | 75,535 | Common | SOLE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $19.9M | 4.22% | 406,469 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $18.0M | 3.84% | 812,821 | Common | SOLE |
| G6674U108 | NVCR | NOVOCURE LTD | $17.1M | 3.64% | 962,396 | Common | SOLE |
| 852312305 | STAA | STAAR SURGICAL CO | $13.3M | 2.83% | 791,879 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $8.9M | 1.90% | 268,783 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $7.7M | 1.65% | 1,274,753 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $7.7M | 1.64% | 145,691 | Common | SOLE |
| 016255101 | ALGN | ALIGN TECHNOLOGY INC | $7.2M | 1.52% | 37,772 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $7.1M | 1.50% | 5,739,013 | Common | SOLE |
| 28238P109 | EHTH | EHEALTH INC | $6.9M | 1.46% | 1,577,850 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $6.3M | 1.35% | 221,021 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $5.9M | 1.25% | 3,429,329 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $4.2M | 0.89% | 444,367 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $3.4M | 0.72% | 118,886 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $3.4M | 0.71% | 239,809 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $3.3M | 0.70% | 64,700 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $3.1M | 0.66% | 39,473 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $2.9M | 0.61% | 1,246,033 | Common | SOLE |
| 09075V102 | BNTX | BIONTECH SE-ADR | $2.7M | 0.57% | 25,206 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $2.5M | 0.54% | 264,976 | Common | SOLE |
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $2.2M | 0.46% | 44,625 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $2.0M | 0.42% | 1,390,028 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $1.8M | 0.38% | 48,750 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC-ADR | $1.7M | 0.37% | 248,934 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $1.7M | 0.36% | 13,334 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $1.6M | 0.35% | 110,719 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $1.5M | 0.32% | 772,652 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $1.4M | 0.30% | 125,861 | Common | SOLE |
| 747324101 | PYXS | PYXIS ONCOLOGY INC | $1.1M | 0.24% | 1,037,421 | Common | SOLE |
| 444859102 | HUM | HUMANA INC | $974,253 | 0.21% | 3,985 | Common | SOLE |
| 01438T106 | ALDX | ALDEYRA THERAPEUTICS INC | $863,531 | 0.18% | 225,465 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $809,896 | 0.17% | 187,911 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC PIPE | $734,966 | 0.16% | 445,434 | Common | SOLE |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $618,353 | 0.13% | 108,865 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $430,311 | 0.09% | 143,437 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $335,650 | 0.07% | 24,500 | Common | SOLE |
| 00972G207 | AKTX | AKARI THERAPEUTICS PLC-ADR | $170,834 | 0.04% | 146,024 | Common | SOLE |
| 37148K100 | GBIOGBX | GENERATION BIO CO | $48,167 | 0.01% | 150,475 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.